1. BMJ Retracts Stem Cell Heart Trial After Investigation, Data Integrity Concerns Referred to Iran FDA
The BMJ has formally retracted a high-profile phase 3 clinical trial on stem cell therapy for heart failure after concluding an investigation into serious concerns about the study's reliability and data integrity. The journal's action follows an expression of concern issued in late 2025, triggered by post-publication s...